Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.68 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28985847 | 0.87 | MAOB (0.58) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL2162276 | 0.84 | CA9 (0.65) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL18141852 | 0.83 | POLB (0.59) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL250038 | 0.83 | MIF (0.60) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL31280892 | 0.83 | MIF (0.60) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL28591504 | 0.82 | MIF (0.74) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL15842248 | 0.81 | ALDH1A1 (0.63) | NPC1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL2552347 | 0.81 | MIF (1.00) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL8764982 | 0.81 | POLB (0.57) | MIFERAP1NPC1ATMTLR9 | |
| SCHEMBL28591500 | 0.80 | NPC1 (0.77) | MIFERAP1NPC1ATMTLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118715462-A | Resin composition for thermosetting photo-alignment film | 日产化学株式会社 | 2024-09-27 | — | — | CN | disclosed |
| CN-112384834-B | Cured film, alignment material, and retardation material | 日产化学株式会社 | 2023-08-11 | — | — | CN | disclosed |
| CN-115975155-A | Composition for forming cured film for alignment material, and retardation material | 日产化学株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-9133184-B2 | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | ANIONA APS (DK) | 2015-09-15 | — | — | US | disclosed |
| US-20140235669-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2014-08-21 | — | — | US | disclosed |
| US-20130040985-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| WO-2012000881-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011117289-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEURO-TRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011092061-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040985-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A1, SLC18A3 | MIF 2660/4885ERAP1 2846/4885NPC1 340/4885 |
| US-20140235669-A1 | CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A1, SLC18A3 | MIF 2660/4885ERAP1 2846/4885NPC1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.